MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12282-023-01513-x

Медицинская библиотека · Breast cancer (Tokyo, Japan) · 2023

Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.

Yoshida Masahiro, Yoshimura Ryo-Ichi, Notake Ryoichi, Shinjo Hidenori, Miyaura Kazunori, Kuwayama Takashi, Kawanaka Takashi, Shien Tadahiko, Yoshio Kotaro, Shiga Toshiko, Kaneyasu Yuko, Nakagawa Tsuyoshi, Kubota Kazunori, Nakamura Seigo, Itami Jun, Working group of APBI with SAVIs in Japan (WASAVIs)

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

A Japanese multi-institutional prospective study was initiated to investigate the effectiveness and safety of accelerated partial breast irradiation (APBI) using strut-adjusted volume implant (SAVI) brachytherapy, with subjects registered between 2016 and 2021. Herein, we report the preliminary results on the feasibility of this treatment modality in Japan, focusing on the registration process, dosimetry, and acute toxicities.

PATIENTS AND

METHODS

Primary registration was conducted before breast-conserving surgery (BCS) and the eligibility criteria included the following: age ≥ 40 years, tumor unifocal and unicentric, ≤ 3 cm in diameter, cN0M0, proven ductal, mucinous, tubular, medullary, or lobular carcinoma by needle biopsy. Secondary registration was conducted after BCS had been performed leaving a cavity for device implantation and pathological evaluations, and the eligibility criteria were as follows: negative surgical margin, tumor ≤ 3 cm in diameter on gross pathological examination, histologically confirmed ductal, mucinous, tubular medullary, colloid, or lobular carcinoma, pN0, L0V0, no extensive ductal component, no initiation of chemotherapy within 2 weeks of the brachytherapy APBI planning with SAVI was performed for the patients successfully entered in the study by the secondary registration process, and the treatment was administered at the dose of 34 Gy in 10 fractions administered twice daily.

RESULTS

Between 2016 and 2021, 64 women were enrolled in the study through primary registration, of which 19 were excluded from the secondary registration process, and in one, it was deemed impossible to comply with the dose constraints established during treatment planning. After the exclusion of these latter 20 patients, we treated the remaining 44 patients by APBI with SAVI. The dose constraints could be adhered to in all the patients, but re-planning was necessitated in 3 patients because of applicator movement during the treatment period. Grade 2 acute toxicities were observed in 18% of all patients, but more severe acute toxicities than Grade 2 were not observed in any of the patients.

CONCLUSION

APBI with SAVI brachytherapy is feasible in Japan from the aspects of compliance with dose constraints and frequency of acute toxicities.

Для цитирования: Yoshida Masahiro, Yoshimura Ryo-Ichi, Notake Ryoichi, Shinjo Hidenori, Miyaura Kazunori, Kuwayama Takashi, Kawanaka Takashi, Shien Tadahiko, Yoshio Kotaro, Shiga Toshiko, Kaneyasu Yuko, Nakagawa Tsuyoshi, Kubota Kazunori, Nakamura Seigo, Itami Jun, Working group of APBI with SAVIs in Japan (WASAVIs). Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.. Breast cancer (Tokyo, Japan). 2023. DOI: 10.1007/s12282-023-01513-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.